Travere Therapeutics Inc
NASDAQ:TVTX
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.26
19.85
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TVTX stock under the Base Case scenario is 22.3 USD. Compared to the current market price of 18.45 USD, Travere Therapeutics Inc is Undervalued by 17%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Travere Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TVTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Travere Therapeutics Inc
Balance Sheet Decomposition
Travere Therapeutics Inc
Current Assets | 324.7m |
Cash & Short-Term Investments | 277.4m |
Receivables | 25.2m |
Other Current Assets | 22.1m |
Non-Current Assets | 179.7m |
PP&E | 21.8m |
Intangibles | 104.2m |
Other Non-Current Assets | 53.6m |
Current Liabilities | 190m |
Accounts Payable | 23.2m |
Accrued Liabilities | 72.1m |
Other Current Liabilities | 94.7m |
Non-Current Liabilities | 344.8m |
Long-Term Debt | 310m |
Other Non-Current Liabilities | 34.9m |
Earnings Waterfall
Travere Therapeutics Inc
Revenue
|
203.4m
USD
|
Cost of Revenue
|
-9.8m
USD
|
Gross Profit
|
193.7m
USD
|
Operating Expenses
|
-473.4m
USD
|
Operating Income
|
-279.7m
USD
|
Other Expenses
|
-71.8m
USD
|
Net Income
|
-351.5m
USD
|
Free Cash Flow Analysis
Travere Therapeutics Inc
USD | |
Free Cash Flow | USD |
TVTX Profitability Score
Profitability Due Diligence
Travere Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Travere Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
TVTX Solvency Score
Solvency Due Diligence
Travere Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Travere Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TVTX Price Targets Summary
Travere Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for TVTX is 21.9 USD with a low forecast of 9.09 USD and a high forecast of 43.05 USD.
Dividends
Current shareholder yield for TVTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 310 full-time employees. The company went IPO on 2003-07-23. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The firm's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker.
Contact
IPO
Employees
Officers
The intrinsic value of one TVTX stock under the Base Case scenario is 22.3 USD.
Compared to the current market price of 18.45 USD, Travere Therapeutics Inc is Undervalued by 17%.